TICKERNERD
Menu
INSPINSPHealthcare · Medical Devices

INSP Stock Forecast: Inspire Medical Systems, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$57
−1.89% on the day

The 17 Wall Street analysts covering Inspire Medical Systems, Inc. hold a median 12-month price target of $60 — +5.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 77 of 100 as at 13 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$1.7B
Ticker Nerd rank
77 / 100
Median analyst target
$60
Analysts covering
17
Total return, dividends reinvested
1W
−5.1%
1M
+16.2%
YTD
−38.1%
1Y
−32.5%
From 52W high
−60.3%
From 52W low
+42.6%
$40
$144
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

INSP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Inspire Medical Systems, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Aug 2026
77 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
99
Value
98
Issuance
86
Revisions
82
Growth
64
Size
39
Volatility
36
Accruals
25
Momentum
10

Quality (99): The business earns solid, repeatable profits on what it owns.

Momentum (10): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

INSP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INSP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100$120$140$160Oct 25Jan 26Apr 26Jul 26INSPHigh $85Median $60Low $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says17 analysts
4 Buy11 Hold2 Sell
Low $40Median $60High $85

The green dot is the last close — the median target sits +5.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
4 Aug 2026BairdMaintainsNeutral$54 → $59
4 Aug 2026Evercore ISI GroupMaintainsIn-Line$40 → $54
4 Aug 2026JP MorganMaintainsNeutral$54 → $60
4 Aug 2026MizuhoMaintainsOutperform$55 → $65
4 Aug 2026OppenheimerUpgradeOutperform$85
4 Aug 2026Piper SandlerMaintainsNeutral$55 → $60
4 Aug 2026Truist SecuritiesReiteratesHold$54 → $62
28 July 2026UBSAssumesSell$67 → $39
16 July 2026Truist SecuritiesMaintainsHold$50 → $54
16 July 2026Truist SecuritiesMaintainsHold—
1 July 2026Freedom Capital MarketsInitiatesBuy—
23 June 2026Evercore ISI GroupDowngradeIn-Line—
7 May 2026OppenheimerMaintainsPerform—
5 May 2026BairdMaintainsNeutral—
5 May 2026Evercore ISI GroupMaintainsOutperform—
5 May 2026JP MorganMaintainsNeutral—
5 May 2026MizuhoMaintainsOutperform—
5 May 2026Piper SandlerDowngradeNeutral—
5 May 2026RBC CapitalMaintainsSector Perform—
5 May 2026StifelMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INSP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

INSP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+39.8%
Analysts raising
1
Analysts cutting
2
Fundamentals

Inspire Medical Systems, Inc. (INSP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
12.6×

Cheaper than 53% of US stocks

Price / sales
1.8×

Cheaper than 55% of US stocks

Price / book
2.0×

Cheaper than 47% of US stocks

EV / EBITDA
19.5×

Cheaper than 17% of US stocks

Growth & margins
Revenue growth (YoY)
−7.6%

Higher than 17% of US stocks

Earnings growth (YoY)
—
Gross margin
85.5%

Higher than 94% of US stocks

Operating margin
−0.3%

Higher than 32% of US stocks

Net margin
15.0%

Higher than 77% of US stocks

Returns & dividend
Return on equity
18.0%

Higher than 79% of US stocks

Return on assets
3.9%

Higher than 71% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

INSP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
INSPInspire Medical Systems, Inc.$1.7B
77
TNDMTandem Diabetes Care, Inc.$1.6B
59
CNMDCONMED Corp.$1.5B
95
ATECAlphatec Holdings, Inc.$1.5B
81
ENOVEnovis Corp.$1.5B
84
IARTIntegra LifeSciences Holdings Corp.$1.4B
89
AORTArtivion, Inc.$1.4B
45

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Inspire Medical Systems, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INSP news & analysis

Is INSP a Buy as Margins Improve but Reimbursement Risks Persist?

Zacks Investment Research · 5 Aug 2026positive

Zacks published an analysis of Inspire Medical, noting its large sleep apnea opportunity, improving margins, and debt-free balance sheet, while acknowledging that reimbursement issues are weighing on procedures. The report suggests these strengths support patience with the company despite the lingering reimbursement risks.

Why it matters — An INSP watcher would care because the analysis weighs the company's improving financial fundamentals against ongoing reimbursement headwinds that currently affect procedure volumes.

INSP Raises 2026 Outlook as Reimbursement Headwinds Start to Ease

Zacks Investment Research · 5 Aug 2026positive

Inspire Medical raised its 2026 outlook after a second-quarter earnings beat, as a favorable Inspire V product mix and cost control offset weak U.S. procedure activity. The company's announcement follows signs that reimbursement headwinds are starting to ease.

Why it matters — INSP watchers would care because an upward revision to the 2026 outlook, supported by product mix and cost controls amid easing reimbursement pressures, signals improving fundamentals despite soft U.S. procedure volumes.

INSP's 28.1% Past-Month Rally Raises a Key Question for Investors

Zacks Investment Research · 5 Aug 2026positive

Inspire Medical shares rose 28.1% over the past month, driven by an earnings beat, raised 2026 guidance, and positive estimate revisions, which offset reimbursement pressure on the company.

Why it matters — INSP watchers would care because the rally signals that strong earnings and guidance are outweighing reimbursement headwinds in investor sentiment.

Inspire Medical Q2 Earnings Beat Estimates, '26 View Raised, Stock Up

Zacks Investment Research · 4 Aug 2026positive

Inspire Medical Systems beat second-quarter earnings estimates and raised its 2026 outlook, with the stock rising on the news. The company did so despite U.S. reimbursement pressures and lower revenues reported in the quarter.

Why it matters — The beat and raised 2026 guidance signal improving expectations for INSP even as headwinds from reimbursement pressures persist.

Inspire Medical Systems Analysts Raise Their Forecasts Following Strong Q2 Results

Benzinga · 4 Aug 2026positive

Inspire Medical Systems reported second-quarter financial results that beat expectations and raised its FY26 guidance, according to Benzinga. Following the strong results, analysts covering the company raised their forecasts.

Why it matters — An INSP watcher would care because better-than-expected results and an upwardly revised FY26 guidance, along with raised analyst forecasts, signal improved near-term expectations for the company.

FAQ

Frequently asked questions about INSP stock

What is the INSP stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Inspire Medical Systems, Inc. have a median 12-month price target of $60, with estimates ranging from $40 to $85. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INSP stock a buy right now?

Of the 17 analysts covering Inspire Medical Systems, Inc., 4 rate it a Buy, 11 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Inspire Medical Systems, Inc. 77 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INSP?

As at 13 Aug 2026, Inspire Medical Systems, Inc. ranks 77 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).

Will INSP stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +5.1% from the last close, and Ticker Nerd's factor model ranks Inspire Medical Systems, Inc. 77 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INSP stock forecast for 2030?

No analyst covering Inspire Medical Systems, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INSP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $85 over the next 12 months.

How has INSP stock performed over the past year?

Inspire Medical Systems, Inc. returned -32.5% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Inspire Medical Systems, Inc. do?

Inspire Medical Systems, Inc. is a medical technology company that develops and commercializes implantable solutions for obstructive sleep apnea.

What is the latest news on INSP?

The most recent item we track (Zacks Investment Research, 5 Aug 2026): "Is INSP a Buy as Margins Improve but Reimbursement Risks Persist?". Zacks published an analysis of Inspire Medical, noting its large sleep apnea opportunity, improving margins, and debt-free balance sheet, while acknowledging that reimbursement issues are weighing on procedures. The report suggests these strengths support patience with the company despite the lingering reimbursement risks.

Company

About Inspire Medical Systems, Inc.

Inspire Medical Systems, Inc. is a medical technology company that develops and commercializes implantable solutions for obstructive sleep apnea. Its core offering is the Inspire system, a neurostimulation therapy designed for patients with moderate to severe sleep apnea who struggle with traditional mask-based treatments such as CPAP. The therapy consists of an implantable pulse generator, sensing and stimulation leads, and a patient remote that allows users to turn the device on and off and adjust settings under clinical guidance. Using a proprietary, closed-loop algorithm, the system continuously monitors breathing during sleep and delivers mild hypoglossal nerve stimulation to help maintain an open airway. Inspire Medical Systems operates primarily in the United States, with an expanding presence in Europe and other international markets, serving sleep medicine specialists, ear-nose-throat surgeons, and hospital systems. Founded in 2007 and headquartered in Golden Valley, Minnesota, the company plays a significant role in the healthcare equipment and therapeutic devices sector by offering a mask-free, minimally invasive alternative for eligible obstructive sleep apnea patients.

CEO Mr. Timothy P. Herbert · 1,333 employees · United States · https://www.inspiresleep.com